Alcobra Ltd. s trend and data analysis indicates that the stock price has dropped -51.49% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -53.85% . Looking at the past 52 week period, the stock price is down -71.71% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Alcobra Ltd. has a negative value of -73.82 compared to overall market performance.Alcobra Ltd. is having a Relative Strength Index of 42.95 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Alcobra Ltd. (NASDAQ:ADHD) has tumbled 4.2% during the past week and has dropped 8.8% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 4.43%. Alcobra Ltd. (NASDAQ:ADHD) has underperformed the index by 9.84% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company shares have received an average consensus rating of Hold for the current week Alcobra Ltd. (NASDAQ:ADHD) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.08 points or 6.56% at $1.14 with 1,276,791 shares getting traded. Post opening the session at $1.2, the shares hit an intraday low of $1.13 and an intraday high of $1.2156 and the price was in this range throughout the day. The company has a market cap of $31 million and the number of outstanding shares has been calculated to be 27,560,920 shares. The 52-week high of Alcobra Ltd. (NASDAQ:ADHD) is $5.75 and the 52-week low is $0.8302.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Alcobra Ltd was Downgraded by Jefferies to Hold on Jan 18, 2017.
Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.